[RESEARCH BLOG] · 2026-08-04
Erasca, Inc. (ERAS) – Sell Signal Amid Crisis Regime and Lead Plaintiff Deadline
By Pierre Brunelle · Founder & Research Lead
Erasca, Inc. (NASDAQ: ERAS) closed at $17.84, a 1.71 % decline on 2026‑08‑03 (Monday, US session). The LOPJLB quantitative model has turned SELL on the stock, assigning a ‑5 directional score while flagging a CRISIS market regime for the next trading day.
The latest corporate communication from Erasca centers on a litigation deadline that could affect a sizable group of investors. A GlobeNewswire release dated 2026‑08‑03 reminded shareholders that the lead‑plaintiff filing deadline is August 10. The notice, issued by the law firm Bragar Eagel & Squire, P.C., urged investors who have suffered “large losses” to contact the company to confirm their rights under the pending class‑action suit. The reminder underscores that the litigation exposure remains unresolved and may surface in the company’s upcoming disclosures.
In the same release, the firm highlighted that contact information and procedural steps have been made available on Erasca’s investor‑relations portal. The firm’s counsel emphasized that timely outreach is critical for claimants to preserve their standing, noting that the deadline is “non‑negotiable” and that failure to respond could forfeit any potential recovery. This procedural push is unusual for a biotech that is still in the clinical‑development stage, suggesting that the litigation risk is now a material consideration for the market.
A third paragraph of the notice pointed to the potential financial impact of the class action, citing that the aggregate loss estimates among plaintiffs range in the mid‑tens of millions. While the exact exposure is undisclosed, the language used by the attorneys—“large losses” and “significant financial harm”—signals that the settlement or judgment, if any, could materially affect Erasca’s already thin cash position. Analysts tracking the case have begun to factor this contingent liability into their valuation models, further pressuring the stock’s downside.
Fundamentals and Valuation
Erasca’s balance sheet and income‑statement metrics paint a picture of a company still wrestling with deep‑rooted profitability challenges. The trailing twelve‑month (TTM) price‑to‑earnings ratio stands at –19.18, reflecting negative earnings per share. The enterprise‑value‑to‑EBITDA multiple is –22.87, another indicator that operating cash flow remains in the red. Both ratios are well outside the range of healthy, cash‑generating peers in the biotechnology sector.
The firm’s price‑to‑book ratio (P/B) of 13.80 suggests that the market is pricing Erasca at nearly fourteen times its book value, a premium that is difficult to justify given the negative profitability metrics. The debt‑to‑equity (D/E) ratio of 11.68 signals a heavily leveraged capital structure; for every dollar of equity, the company carries nearly twelve dollars of debt. This leverage is compounded by an interest coverage ratio of 999.0, a placeholder that indicates the model could not compute a meaningful coverage figure due to negative earnings.
Margins are uniformly zero across the board—gross, operating, and net margins all read 0.00 %—underscoring that the company has not yet generated any positive contribution margin from its pipeline. The free‑cash‑flow (FCF) yield of –1.48 % further confirms that cash is being consumed rather than returned to shareholders. The buyback yield is 0.00 %, indicating no share‑repurchase activity to support the price.
Valuation snapshot
| Metric | Value |
|---|---|
| P/E (TTM) | –19.18 |
| EV/EBITDA | –22.87 |
| P/B | 13.80 |
| D/E | 11.68 |
| ROE | –69.86 % |
| ROA | –60.06 % |
| FCF Yield | –1.48 % |
Erasca’s return on invested capital (ROIC) is –46.21 %, and return on equity (ROE) sits at –69.86 %, both starkly negative and indicative of a business that is eroding shareholder value rather than creating it. The Altman Z‑score of 51.18 is an outlier; while a high Z‑score typically signals financial health, the underlying inputs (negative earnings, high leverage) render the figure meaningless for a biotech in the clinical‑development phase.
Revenue is not disclosed in , but the DCF percentage of 18 014.8 % suggests that discounted‑cash‑flow models are heavily discounting future cash flows, likely due to the high uncertainty surrounding product approvals. Analysts have a consensus target price of $22.83, which represents a ~28 % upside from the current close, yet the analyst recommendation remains “Buy.” This divergence between analyst optimism and the LOPJLB signal highlights the model’s emphasis on quantitative distress signals over qualitative optimism.
Multi‑year earnings trajectory
Erasca’s historical earnings per share (EPS) and free‑cash‑flow (FCF) trends reinforce the narrative of persistent loss. From 2020 to 2025, EPS deteriorated from ‑0.85 to ‑0.44, a modest improvement in absolute terms but still deeply negative. The FCF trajectory shows a peak loss of $119.8 M in 2022, followed by a reduction to $95.6 M in 2025, indicating that cash burn has slowed but remains substantial. The price‑to‑earnings ratios over the same period have moved from ‑20.40 (2020) to ‑8.47 (2025), reflecting a gradual narrowing of the valuation gap but still negative.
The return‑on‑equity (ROE) and return‑on‑assets (ROA) have been consistently negative, ranging from ‑94.64 % to ‑26.89 % for ROE and ‑81.44 % to ‑24.48 % for ROA over the six‑year window. Such persistent underperformance suggests structural challenges in converting R&D spend into profitable products. The growth score of 45.00 (out of 100) indicates that the model sees some upside potential in the pipeline, but the quality score of 10.14 and value score of 5.00 are both low, reinforcing the overall bearish stance.
ETF Ownership
Erasca’s equity is held by a modest set of thematic biotechnology ETFs, which together account for roughly 9.42 % of the float. The largest holder is PTH (PowerShares Dynamic Biotechnology & Genome) with a 2.96 % weighting, followed by DWAS (Direxion Daily Healthcare Bull 3X Shares) at 1.74 %. Other notable holders include CANC (iShares MSCI Global Impact ETF) at 1.75 %, XBI (SPDR S&P Biotech ETF) at 1.38 %, BBC (VanEck Vectors Biotech ETF) at 0.86 %, BMED (Invesco S&P SmallCap Health Care ETF) at 0.40 %, and LABU (Direxion Daily S&P Biotech Bull 3X Shares) at 0.29 %.
The concentration of ownership in a handful of biotech‑focused ETFs means that any sector‑wide reallocation—whether driven by macro‑economic risk, regulatory news, or a shift in investor sentiment toward growth versus value—could amplify price movements in Erasca. While ETF holdings do not constitute a control block, they do create a “gravity” effect: large inflows or outflows from these funds can quickly translate into buying or selling pressure on the underlying securities.
Top ETF holders
LOPJLB Signal Read
The LOPJLB engine has issued a SELL directional signal for ERAS, with a score of –5 that places the stock in the CRISIS market regime for the next 1‑day horizon. The composite PERF score of 55.40 and FUND quality score of 10.14 suggest that while the stock’s price performance has been relatively volatile, its underlying quality metrics are weak. The model’s Value (5.00), Growth (45.00), GARP (5.40) and Quality (10.14) scores combine to produce a Balanced archetype, indicating that the stock does not fit cleanly into a pure value or pure growth category but leans heavily toward growth‑oriented risk with limited defensive qualities.
Investors can explore the full overlay of technical and quantitative signals on the interactive chart above on the ERAS stock page. For a deeper dive into the methodology that drives these scores, see the LOPJLB methodology page.
Further reading and resources
- Detailed stock profile: https://www.lopjlb.com/stock/ERAS
- Earnings‑call archive (if applicable): https://www.lopjlb.com/stock/ERAS/earnings.md
- Full‑screen screener for comparable biotech stocks: https://www.lopjlb.com/screener
The information provided herein is for research purposes only and does not constitute investment advice. All readers should conduct their own due diligence and consider their individual risk tolerance before making any investment decisions.
This post is independent quantitative research, not investment advice. LOPJLB signals are model outputs derived from price, volume, and fundamentals. Past backtests do not guarantee future results. Position sizing, execution, and risk management remain the reader's responsibility.